← Back to home

Patients with bietti crystalline corneoretinal dystrophy (carrying biallelic CYP4V2 mutations)

Clinical trials for Patients with bietti crystalline corneoretinal dystrophy (carrying biallelic CYP4V2 mutations) explained in plain language.

Never miss a new study

Get alerted when new Patients with bietti crystalline corneoretinal dystrophy (carrying biallelic CYP4V2 mutations) trials appear

Sign up with your email to follow new studies for Patients with bietti crystalline corneoretinal dystrophy (carrying biallelic CYP4V2 mutations), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

Experimental gene therapy offers hope for rare blindness condition

Disease control By invitation only

This study provides ZVS101e, a gene therapy, to 32 people with Bietti crystalline corneoretinal dystrophy (BCD) who were in the control group of a previous Phase III trial. The therapy uses a harmless virus to deliver a working gene to the eye, aiming to slow vision loss. The mai…

Matched conditions: PATIENTS WITH BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY (CARRYING BIALLELIC CYP4V2 MUTATIONS)

Sponsor: Chigenovo Co., Ltd • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC

Patients with bietti crystalline corneoretinal dystrophy (carrying biallelic CYP4V2 mutations)

Get alerted when new Patients with bietti crystalline corneoretinal dystrophy (carrying biallelic CYP4V2 mutations) trials appear

Experimental gene therapy offers hope for rare blindness condition